Articles related to FDA

Explore the latest advancement in NSCLC treatment: the FDA-approved amivantamab combo has demonstrated a significant leap in progression-free survival for patients with specific genetic mutations, reshaping the standard of care.

Explore the recent FDA approval of biweekly teclistamab dosing for multiple myeloma, a significant stride in offering personalized treatment schedules that cater to patient and clinician needs.

Amtagvi’s approval introduces a novel approach in the treatment of advanced melanoma, employing patient-derived TIL-cell therapy to target tumors with precision, offering a beacon of hope for those with limited options.

Better Therapeutics’ digital therapeutic app has been recognized with FDA breakthrough device status, showcasing its potential in significantly reducing liver fat in patients with advanced liver disease through cognitive behavioral therapy.

Healthcare professionals are navigating a complex dialogue on COVID-19 vaccine shedding, underscored by FDA acknowledgments and Pfizer protocols that hint at the nuanced risks of gene therapy product exposure.

The recent recall of Zenzedi 30 mg tablets due to contamination stresses the importance of meticulous medication management and awareness of the broader challenges in ADHD treatment availability and safety.